Recursion releases open-source data from largest ever dataset of biological images and a machine learning competition available through NeurIPS 2019. Recursion Releases Open-Source Data from ...

One outcome of the big data efforts is a new, publicly available data set that Recursion released in May, called the RxRx1. It consists of 300 gigabytes of over 100,000 images "representing ...

Revisiting Recursion: Big Bets, Big Data, And The Big Cash Burn Rate Apr. 10, 2024 5:12 AM ET Recursion Pharmaceuticals, Inc. (RXRX) Stock RXRX 4 Comments 3 Likes Nelson Alves ...

Recursion: Shaking Up The Biopharma Landscape With A Bold, Data-Driven Blueprint Jul. 17, 2023 5:04 PM ET Recursion Pharmaceuticals, Inc. (RXRX) Stock NVDA , RXRX 21 Comments 4 Likes Nelson Alves ...

By generating these ever-growing phenomics data alongside algorithms enabling their relatability across experiments, time and disease modality, Recursion is building functional maps of human biology.

Shares of Recursion Pharmaceuticals Inc. (NASDAQ: RXRX) are trading higher after the company, in collaboration with MIT, announced the release of Boltz-2, a new open-source AI model designed to ...

With additional patient-centric data, compute power, and an exciting new focus for its Bayer collaboration, the company is accelerating the shift of biotech to techbioSALT LAKE CITY, Nov. 09, 2023 ...

Recursion, a drug discovery startup out of Salt Lake City, Utah has announced a $60 million Series B round, led by Data Collective (DCVC). Recursion started out in 2014 on a mission to identify ...

HealthVerity, the leader in real-world data (RWD) technology and privacy-compliant data exchange, today announced that Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding ...